{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:05:07Z","timestamp":1773090307664,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,1,20]],"date-time":"2019-01-20T00:00:00Z","timestamp":1547942400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,21]]},"DOI":"10.1093\/eurheartj\/ehy697","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T12:30:32Z","timestamp":1545309032000},"page":"1009-1012","source":"Crossref","is-referenced-by-count":19,"title":["Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?"],"prefix":"10.1093","volume":"40","author":[{"given":"Rodney H","family":"Falk","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital\/Dana Farber Cancer Institute Amyloidosis Program, 75 Francis St, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B1","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/13506129.2015.1063485","article-title":"Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)","volume":"22","author":"Cho","year":"2015","journal-title":"Amyloid"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B5","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B6","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","article-title":"Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area","volume":"263","author":"Cortese","year":"2016","journal-title":"J Neurol"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815","article-title":"Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)","author":"Maurer","year":"2017","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","author":"Martinez-Naharro","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B11","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B12","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-125-6-199609150-00009","article-title":"Resolution of heart failure in patients with AL amyloidosis","volume":"125","author":"Dubrey","year":"1996","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B15","doi-asserted-by":"crossref","first-page":"E7710","DOI":"10.1073\/pnas.1801117115","article-title":"Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans","volume":"115","author":"Madhivanan","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B17","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJM198709173171205","article-title":"Senile cardiac amyloidosis with myocardial dysfunction. Diagnosis by endomyocardial biopsy and immunohistochemistry","volume":"317","author":"Olson","year":"1987","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B20","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B21","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019032104564617900_ehy697-B22","author":"Dorbala","year":"2016"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/12\/1009\/28170678\/ehy697.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T08:57:57Z","timestamp":1553158677000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/40\/12\/1009\/5296359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,1,18]]},"published-print":{"date-parts":[[2019,3,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehy697","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3,21]]},"published":{"date-parts":[[2019,1,18]]}}}